Literature DB >> 1401941

Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

A Casadevall1, J Mukherjee, M D Scharff.   

Abstract

Mouse monoclonal antibody (MAb)-based enzyme-linked immunosorbent assays (ELISAs) have been developed to detect Cryptococcus neoformans capsular polysaccharide from the four serotypes A, B, C and D. The ELISAs avoid the problem of unreliable polysaccharide binding to polystyrene plates by using MAbs to capture and immobilize the polysaccharide antigen. The presence of polysaccharide is detected using MAbs of a different isotype from that of the capture MAb. The capturing MAbs are themselves immobilized on the plates using commercial goat anti-mouse polyclonal sera. The MAbs bind to the glucuronoxylomannan component of cryptococcal polysaccharide. The ELISAs can be used to measure the concentration of polysaccharide in biological fluids and are potentially useful tools for basic research and clinical studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401941     DOI: 10.1016/0022-1759(92)90209-c

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  96 in total

1.  Methamphetamine Impairs IgG1-Mediated Phagocytosis and Killing of Cryptococcus neoformans by J774.16 Macrophage- and NR-9640 Microglia-Like Cells.

Authors:  Lilit Aslanyan; Hiu H Lee; Vaibhav V Ekhar; Raddy L Ramos; Luis R Martinez
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.

Authors:  D L Goldman; S C Lee; A J Mednick; L Montella; A Casadevall
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport.

Authors:  Marcio L Rodrigues; Leonardo Nimrichter; Débora L Oliveira; Susana Frases; Kildare Miranda; Oscar Zaragoza; Mauricio Alvarez; Antonio Nakouzi; Marta Feldmesser; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2006-11-17

5.  Changes in glucosylceramide structure affect virulence and membrane biophysical properties of Cryptococcus neoformans.

Authors:  Shriya Raj; Saeed Nazemidashtarjandi; Jihyun Kim; Luna Joffe; Xiaoxue Zhang; Ashutosh Singh; Visesato Mor; Desmarini Desmarini; Julianne Djordjevic; Daniel P Raleigh; Marcio L Rodrigues; Erwin London; Maurizio Del Poeta; Amir M Farnoud
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-09-01       Impact factor: 3.747

6.  Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations.

Authors:  Leonardo Nimrichter; Susana Frases; Leonardo P Cinelli; Nathan B Viana; Antonio Nakouzi; Luiz R Travassos; Arturo Casadevall; Marcio L Rodrigues
Journal:  Eukaryot Cell       Date:  2007-06-15

7.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

9.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.